Cancer vaccines: a promising field starting to come of age?

At present, cancer vaccines are available mainly as part of clinical trials but, with ambitious biotech companies starting to grab the attention of big pharma and other investors with deep pockets, the global market for these immunotherapies is set to expand rapidly.

Worth an estimated $9 billion in 2023, the global cancer vaccines market’s value is expected to jump to $24.22 billion by 2033 by registering a compound annual growth rate of 12% in this period, according to a report from Future Market Insights.

Unlike vaccines to protect us from disease, cancer treatment vaccines are for people who already have the disease. Taking these products to market has proven even more challenging than for other vaccines.